<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05117554</url>
  </required_header>
  <id_info>
    <org_study_id>ARC-14</org_study_id>
    <secondary_id>2021-003856-17</secondary_id>
    <nct_id>NCT05117554</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers</brief_title>
  <official_title>A First-in-human, Participant and Investigator-blinded, Randomized, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521, in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcus Biosciences, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability and the pharmacokinetic and&#xD;
      pharmacodynamic profile of AB521 in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 4, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Changes From Baseline in Laboratory Parameter Values</measure>
    <time_frame>Baseline; Up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Changes from Baseline in Vital Sign Values</measure>
    <time_frame>Baseline; Up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of AB521</measure>
    <time_frame>multiple timepoints up to approximately 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Hour 0 to the Last Sample With Measurable Plasma Concentrations (AUClast) of AB521</measure>
    <time_frame>multiple timepoints up to approximately 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Occurrence of Cmax (tmax) of AB521</measure>
    <time_frame>multiple timepoints up to approximately 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Rate Constant (λz) of AB521</measure>
    <time_frame>multiple timepoints up to approximately 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-Life (t1/2) of AB521</measure>
    <time_frame>multiple timepoints up to approximately 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Hour 0 to Infinity (AUCinf) of AB521</measure>
    <time_frame>multiple timepoints up to approximately 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution of AB521</measure>
    <time_frame>multiple timepoints up to approximately 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Body Clearance</measure>
    <time_frame>multiple timepoints up to approximately 13 days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>AB521 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive &quot;Dose 1&quot; of AB521 orally with water under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AB521 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive &quot;Dose 2&quot; of AB521 orally with water under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AB521 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive &quot;Dose 3&quot; of AB521 orally with water under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AB521 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive &quot;Dose 4&quot; of AB521 orally with water under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo orally with water under fasting conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB521</intervention_name>
    <description>Capsule</description>
    <arm_group_label>AB521 Dose 1</arm_group_label>
    <arm_group_label>AB521 Dose 2</arm_group_label>
    <arm_group_label>AB521 Dose 3</arm_group_label>
    <arm_group_label>AB521 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who are healthy volunteers (in the opinion of the investigator) as&#xD;
             determined by pre-study medical history, physical examination, vital signs, and&#xD;
             12-lead electrocardiogram (ECG)&#xD;
&#xD;
          -  Participants must have clinical laboratory tests within the reference range for age&#xD;
             and gender at screening and baseline.&#xD;
&#xD;
          -  Screening and randomization hemoglobin ≥12.5 grams/deciliters (7.7 millimoles/liters)&#xD;
&#xD;
          -  Participants should have adequate peripheral venous access.&#xD;
&#xD;
          -  Body weight of 45 kilograms (kg) or greater and body mass index within the range of 18&#xD;
             to 32 kg/meters squared (m^2) (inclusive)&#xD;
&#xD;
          -  Male participants must be vasectomized and have been vasectomized for at least 3&#xD;
             months prior to screening visit with confirmed history of azoospermia subsequent to&#xD;
             the vasectomy procedure&#xD;
&#xD;
          -  Contraceptive use should be consistent with local regulations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has any (acute or chronic [including severe acute respiratory syndrome coronavirus 2&#xD;
             (SARS-CoV-2) infection]) medical or psychiatric condition that, in the opinion of the&#xD;
             investigator, could jeopardize or would compromise the study participant's ability to&#xD;
             participate in this study&#xD;
&#xD;
          -  Has history or presence of cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrinological, hematological, cerebrovascular, neurological, or&#xD;
             other major disorders capable of significantly altering the absorption, metabolism, or&#xD;
             elimination of investigational drug; constituting a risk when taking the study&#xD;
             intervention; or interfering with the interpretation of data in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          -  Abnormal blood pressure (BP) or pulse measurements at the Screening Visit or Day -2/-1&#xD;
             (Admission) in a supine position after 5 minutes of rest as follows: mean systolic BP&#xD;
             ≥139 millimeters of mercury (mm Hg) or mean diastolic BP ≥89 mm Hg&#xD;
&#xD;
          -  Liver enzyme test results: Alanine aminotransferase, aspartate aminotransferase,&#xD;
             bilirubin, or alkaline phosphatase &gt;1.0x the upper limit of normal&#xD;
&#xD;
          -  Current or chronic history of liver disease or known hepatic or biliary abnormalities&#xD;
&#xD;
          -  Has 12-lead electrocardiogram with changes considered to be clinically significant at&#xD;
             the Screening Visit or day of admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Arcus Biosciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Director</last_name>
    <phone>510-694-6220</phone>
    <email>clinicaltrials@arcusbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AB521</keyword>
  <keyword>HIF-2α</keyword>
  <keyword>hypoxia-inducible factor 2 alpha</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

